Medical Weight Loss for Winooski, Vermont Residents

Winooski, Vermont residents get physician-supervised weight loss by telehealth from New Hope Weight Loss: a $119 doctor review, then compounded semaglutide from $166/month or tirzepatide from $233/month.

Physician-supervised GLP-1 programs from $166/month, serving Winooski through telehealth from our Costa Mesa, California clinic. Doctor review $119. Over 5,400 patients treated.

Wondering if you qualify in Winooski? Eligibility for compounded GLP-1 care is confirmed by Dr. Sharma during your video visit, based on your health history, not your zip code in Vermont. Doctor review just $119 (medication separate).

Why Winooski Residents Choose New Hope Weight Loss

We made New Hope easy to start without making it less serious. A Winooski patient can go from first visit to a physician-approved plan without insurance paperwork, prior authorizations, or a single drive to an office. The $119 review with Dr. Anjmun Sharma is flat, the medication price is published, and the whole thing happens by telehealth. Low friction to begin, real medicine once you do, the same standard everyone in Vermont gets.

Winooski is served by telemedicine from our Costa Mesa, California clinic. The same physician-supervised semaglutide and tirzepatide programs are available by secure video, with medication shipped to your door.

People throughout Winooski reach the same physician-supervised care that built our reputation in Costa Mesa, and they do it from home, because telehealth erases the gap between Vermont and California. We care for patients throughout downtown Winooski and the greater Chittenden County area near Burlington. Because everything happens by telehealth, patients across downtown Winooski and the greater Chittenden County area near Burlington get the same physician-led program without driving anywhere or sitting in a waiting room.

Most people across Winooski do not wait for an opening, they pick a time, meet Dr. Sharma by video, and can begin treatment within days. If you would rather spread payments out, Winooski patients can use Klarna or Affirm at checkout instead of paying the full cost at once. Even in the rural reaches of Vermont, New Hope Weight Loss reaches patients by secure telehealth from our Costa Mesa, California clinic, so distance never limits your physician-supervised care.

GLP-1 Weight Loss Programs Available

Begin your reset: semaglutide, from $166/mo

The 90-Day Metabolic Reset gives Winooski patients a structured three-month plan with semaglutide, the active ingredient shared with Wegovy and Ozempic. Choose $166 a month or $499 for the whole 90 days. In trials of the branded drug, the average was around 15 to 17 percent body-weight loss. Compounded semaglutide is not FDA-approved and not brand-identical, and results vary.

Go further: tirzepatide, from $233/mo

Tirzepatide hits both GLP-1 and GIP receptors for a dual effect. Qualifying doses in branded-drug trials reached up to 22.5 percent loss, which is not what most patients should expect. It carries the same active ingredient as Mounjaro and Zepbound.

Each plan begins with a $119 physician review. Medication is billed separately. HSA, FSA, Klarna, and Affirm accepted.

How Telehealth Works for Winooski

Getting started in Winooski is simple, and you never have to leave home. Begin with a short intake quiz about your health history, weight goals, and any medications you take. Dr. Anjmun Sharma reviews your answers and meets you by secure video, usually within 48 hours, to talk through whether compounded semaglutide or tirzepatide is a reasonable fit. If she prescribes, a state-licensed 503(a) pharmacy ships your medication straight to your Winooski address in cold-pack packaging that keeps it stable in transit. From there, your follow-up visits happen by video too, so dose checks and questions stay easy no matter where in you live.

Frequently Asked Questions, Winooski

How does someone in Winooski access New Hope Weight Loss?

Access from Winooski is entirely online. Our one physical clinic stands in Costa Mesa, California, while we serve Winooski, Vermont through telehealth. To begin, Dr. Anjmun Sharma meets you over secure video, reviews your background, and confirms whether you are eligible for a compounded GLP-1 program.

Is a clinic visit part of the process for Winooski residents?

A clinic visit is never part of it for Winooski. The model is fully telehealth, so your consult, refills, and check-ins happen from home. After Dr. Sharma approves you, medication is shipped to Winooski inside cold-pack packaging designed to maintain a steady temperature during transit.

What are the fees for Winooski patients?

The physician review costs $119. Compounded semaglutide runs from $166 each month, or $499 for the 90-day program, and tirzepatide from $233 each month. Medication is billed on its own. We honor HSA, FSA, Klarna, and Affirm, and Winooski residents are charged no distance surcharge.

What areas of Winooski do you serve?

We serve patients from across Winooski by telehealth, including downtown Winooski and the greater Chittenden County area near Burlington.

Is bilingual (Spanish) telehealth care available for Winooski patients?

Yes. Anamaria Schmidt, our bilingual clinical coordinator, handles calls, WhatsApp, and Spanish-language consultations, with Dr. Sharma supervising every case. The full telehealth program, intake, consultation, and follow-up, is available in Spanish for Winooski patients.

Winooski Residents, Get Started Today

Doctor review $119. Semaglutide from $166/mo. Tirzepatide from $233/mo. Medication separate.

Start My Journey →

New Hope Weight Loss | clinic at 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626 | (657) 837-3342 | Serving Winooski, Vermont by telehealth. Telehealth availability and eligibility are confirmed during the medical consultation.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with or endorsed by these companies. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality.